About 415 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 642 million people by 20401. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, and basal insulin from our alliance partner Eli Lilly and Company, we are also focused on cardiometabolic indications with a high unmet medical need.
IntroDia™ is the largest multinational survey of its kind to date which aims to investigate early conversations between physicians and people living with type 2 diabetes and how these conversations may correlate with the individuals’ wellbeing and self-care. Launched in 2013, the survey includes insights from more than 10,000 individuals with type 2 diabetes and more than 6,700 treating physicians across 26 countries. Learn more about the results.
The study is investigating conversations at two distinct milestones: the point of diagnosis of type 2 diabetes, and the moment when additional therapy may be required. The survey insights will be used to develop tools to provide additional support for physicians and people with type 2 diabetes for their early conversations. IntroDia™ was developed by Boehringer Ingelheim and Eli Lilly and Company together with an international multidisciplinary Advisory Board, and in partnership with the International Diabetes Federation (IDF).
Latest data from the #IntroDia Survey shows that most of the Canadian physicians surveyed agreed that conversations with patients at diagnosis of #T2D are important but challenging, and most would like tools or other types of support for these conversations.
Find out more about the #IntroDia Survey here: bit.ly/1yd9ZRC